Oxidative stress and inflammation play a pathogenetic role in idiopathic environmental intolerances (IEI), namely, multiple chemical sensitivity (MCS), chronic fatigue syndrome (CFS), fibromyalgia (FM), electromagnetic hypersensitivity (EHS), amalgam disease, and others [1]. The clinical IEI features include multiorgan manifestations in respiratory, nervous, cardiological, endocrine, cutaneous, and gastrointestinal systems, often without classic allergologic and/or immunologic markers [1–3]. In many cases, disease onset appears to be preceded by a short-term stress, most commonly a chemical overexposure in the case of MCS, infections in CFS, and physical trauma in FM, and then followed by a chronic condition that typically lasts for years or decades (for recent review see [2, 4, 5]).

The inherited or acquired impaired metabolism of xenobiotics has been postulated as a molecular basis for IEI pathogenesis. It has recently been demonstrated that some genetic variants of drug metabolizing and detoxifying enzymes, such as cytochrome P450 reductase (CYP), glutathione-S-transferase (GST), N-acetyl-transferase (NAT), and superoxide dismutase (SOD2), may be considered genetic determinants of IEI risk [2, 6–9].

These genetic polymorphisms seem to be connected to the loss of efficiency of detoxification systems, disturbances of free radical/antioxidant homeostasis, and increased production of inflammatory cytokines [1, 10, 11]. The overlapping
symptoms among various IEI have prompted several investigators to hypothesize that they may share a common pathogenetic feature, and the most suitable one proposed so far is the increased nitric oxide/peroxynitrite levels. In fact, short-term stressors are able to increase systemic nitric oxide production [12, 13], which in the reaction with superoxide forms the potent oxidant peroxynitrite. Peroxynitrite, in turn, can act through six different positive feedback loop mechanisms to increase the levels of nitric oxide and its other precursor, superoxide anion, to form more peroxynitrite in a vicious cycle [14, 15].

Interestingly, it has recently been reported that gene variants of NOS2 are associated with alteration of NO levels in inflammatory bowel disorders, asthma, atopy, and migraine [16–20], all of which are comorbidities shared by IEI. Furthermore, circulating NO levels may also be affected by some variants of NOS3 gene [21].

This clinical case-control study aimed at investigating the association, if any, of the promoter pentanucleotide microsatellite −2.5 kb (CCTTT), and the Ser608Leu polymorphisms in NOS2 gene and the −786T>C polymorphism in NOS3 promoter with different IEI, such as MCS, suspected MCS (SMCS), FM, and CFS. We also attempted to find out a correlation between the indicated polymorphisms and serum levels of nitrite/nitrate.

2. Materials and Methods

2.1. Study Cohorts. Three hundred and sixty-seven Italian patients, who presented with symptoms compatible with IEI, were enrolled in this study at Department of Medical Pathophysiology, University of Rome "La Sapienza," Policlinico Umberto I, and at Istituto Dermopatico dell’Immacolata (IDI IRCCS) in Rome, Italy (Ethical Committee Board Approval, Istituto Dermopatico dell’Immacolata—IDI IRCCS, Rome, Italy, n.121/CE/2008).

Diagnosis was set based on the medically assessed results of the modified QESI (quick environmental exposure and sensitivity inventory) scoring [22]. QESI is a validated self-administered questionnaire developed as a screening tool for patients with IEI. It is based on five different scales of assessment: symptoms severity, chemical triggers, other triggers, life impact, and finally a masking index to ongoing exposures [22]. A modified QESI score of 10 common environmental exposures and 10 major symptoms enabled the differential diagnosis of MCS and SMCS (suspected MCS): full diagnosis (20 ≤ score ≤ 30) or strongly suspected diagnosis, that is, subjects fulfilling diagnostic criteria only partially (10 ≤ score ≤ 20) or subjects excluded from enrollment (0 ≤ score ≤ 10) [10].

One hundred and seventy of the recruited subjects were consecutive patients with MCS (49M/121F; 49 ± 11 years), 108 were consecutive patients with SMCS (90F/18M; 49 ± 12 years), who partly corresponded to the above reported diagnostic criteria, and 89 were consecutive patients (67F/22M; 47 ± 10 years) presenting with either fibromyalgia or chronic fatigue syndrome (FM/CFS).

One hundred and ninety-six healthy Italian subjects (M = 59, F = 137; 45.5 ± 9 years) were selected as controls among healthy staff members of participant institutions, Istituto Dermopatico dell’Immacolata (IDI IRCCS) in Rome and University of Messina, according to the established criteria as follows: (i) an absence of any clinically diagnosed disease, in particular allergic or immunologic disturbances, (ii) no drug or nutraceutical supplement since at least six weeks, at the time of blood sampling, and (iii) whole blood total production of reactive oxygen and nitrogen species (ROS/RNS) below 650 cps/L, as determined by luminol-dependent chemiluminescent response to phorbol 12-myristate 13-acetate [23] (subject recruitment under study protocol approved by Istituto Dermopatico dell’Immacolata—IDI IRCCS, Rome, Italy—Ethical Committee, n.52/CE/2010).

Nonsmokers in the patients’ group were 81.4%, smokers 11.3%, and patients with undetermined smoking habits 7.3%. Nonsmokers in the control group were 85.2%. No alcohol or drug abusers were present among patients or controls.

Blood samples were drawn after all subjects provided written informed consent. The study was carried out in accordance with the Declaration of Helsinki (1964), and the study protocol was approved by the local Ethics Committee.

2.2. Genotyping for Single Nucleotide Polymorphisms NOS2A Ser608Leu and NOS3 −786T>C. Genomic DNA was isolated from peripheral leukocytes by PureGene DNA Purification System kit (Gentra Qiagen, Milan, Italy). Genotyping for the single nucleotide polymorphisms (SNPs) NOS2A Ser608Leu (C2087T; rs2297518) and NOS3 −786T>C (rs2070744) was performed by real-time PCR allelic discrimination, using TaqMan-Based Genotyping Assays (Applied Biosystems; assay ID: C_1889257_10; C_15903663_10) available from Life Technologies (Monza, Italy) in a 96-well plate on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The reactions were carried out in a final volume of 20 μL containing 1x TaqMan Genotyping Master Mix, 1x TaqMan-based specific assay, and 10 ng genomic DNA, using thermal cycling conditions suggested by manufacturer’s protocols.

2.3. Genotyping for NOS2A Pentanucleotide Microsatellite −2.5 kb (CCTTT). Genotyping for the pentanucleotide microsatellite −2.5 kb (CCTTT), in NOS2A promoter was carried out by DNA direct sequencing. PCR reactions were carried out in a final volume of 50 μL, containing 100 ng of genomic DNA, 1x PCR buffer, 1.7 mM Mg2Cl2, 0.2 mM dNTP, 0.2 μM primers, and 1 U EuroTaq DNA polymerase (EuroClone, Milan, Italy), in One Personal thermocycler (Celbio, Milan, Italy), using the following thermal cycling conditions: initial denaturation at 95 °C for 10’, then 40 cycles of 95°C for 20”, 56°C for 20”, 72°C for 20”, and finally a full extension step at 72°C for 7”. PCR primer sequences were the same used by Holla and coworkers [16].

PCR products were purified and the sequencing reaction was performed with BigDye Terminator v1.1 Cycle Sequencing kit (Applied Biosystems, Applera Corp., Milan, Italy). The reaction was carried out in a final volume of 20 μL containing 30 ng of purified PCR product, 1.6 pmol of forward primer, 2.5x ready reaction mix, 5x sequencing buffer, and DNase/RNase free water, in a thermocycler
Table 1: Allele and genotype frequencies of NOS2A and NOS3 SNPs in IEI patients and healthy subjects.

| Genotype                  | MCS (N = 170) | SMCS (N = 108) | FM/CFS (N = 89) | Controls (N = 196) |
|---------------------------|---------------|----------------|-----------------|--------------------|
| NOS2A C2087T (Ser608Leu)  |               |                |                 |                    |
| CC (Ser/Ser)              | 60.6%         | 52.8%          | 65.2%           | 60.2%              |
| CT (Ser/Leu)              | 34.7%         | 41.7%          | 30.3%           | 36.2%              |
| TT (Leu/Leu)              | 4.7%          | 5.6%           | 4.5%            | 3.6%               |
| C allele frequency        | 0.78          | 0.74           | 0.80            | 0.78               |
| T allele frequency        | 0.22          | 0.26           | 0.20            | 0.22               |
| −786T>C NOS3              |               |                |                 |                    |
| TT                        | 32.9%         | 34.3%          | 33.7%           | 33.2%              |
| TC                        | 45.9%         | 46.3%          | 49.4%           | 44.5%              |
| CC                        | 21.2%         | 19.4%          | 16.9%           | 22.3%              |
| T allele frequency        | 0.56          | 0.56           | 0.58            | 0.55               |
| C allele frequency        | 0.44          | 0.44           | 0.42            | 0.45               |

MCS, multiple chemical sensitivity; SMCS, suspected multiple chemical sensitivity; FM/CFS, fibromyalgia/chronic fatigue syndrome; controls, healthy subjects.

Hybaid ThermoSprint (Celbio, Milan, Italy). The thermal cycling conditions were 96°C for 3', then 28 cycles of 10' at 96°C, 10' at 50°C, 4' at 60°C, and finally 5' at 4°C. The sequencing products were purified and analysed with ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Applera Corp., Milan, Italy).

2.4. Statistical Analysis. To compare NOS2A and NOS3 allele and genotype frequencies in patients and controls, as well as deviations of genotype distributions from Hardy-Weinberg equilibrium, Fisher's exact test was used.

Statistical analysis was performed using the GraphPad Prism 4 software (San Diego, CA, USA).

The linkage disequilibrium extent between the two NOS2 polymorphisms was estimated by Haploview v4.2, by collecting the (CCTTT)_n alleles in two categories according to the number of repeats; that is, the alleles with <12 repeats were designated as s (short) and alleles with ≥12 repeats as l (long) alleles.

Statistical analysis of nitrite/nitrate variations in patients and controls was performed using STATISTICA 7.0 program (StatSoft Inc., Tulsa, OK, USA). Nitrite/nitrate plasma concentration values were presented as median, lower, and upper quartiles, minimum and maximum. Nitrite/nitrate plasma levels in either patients or controls having different NOS2A and NOS3 genotypes were analysed by one-way ANOVA. The differences in nitrite/nitrate plasma levels among the subgroups of patients and controls were analysed by two-way ANOVA. If necessary, P values were adjusted for multiple comparisons using the Bonferroni adjustment.

A P value of 0.05 or lower was regarded as statistically significant.

3. Results

3.1. Allele and Genotype Frequencies of NOS2A and NOS3 SNPs. Genotype and allele frequencies of NOS2A and NOS3 SNPs examined in IEI patients (MCS, SMCS, and FM/CFS) and controls are shown in Table 1. The genotype frequencies did not deviate from the expected value by Hardy-Weinberg equilibrium.

Genotyping for the SNP C2087T (Ser608Leu) in NOS2A showed that allele frequencies in patients were not statistically significant different in comparison with controls. The wild-type allele C was the most frequent in all groups and almost entirely represented by the homozygous genotype.

The CC2087 genotype frequency was higher in FM/CFS group than in all the other groups, and it tended to a statistically significant difference only in comparison with SMCS group (P = 0.08) that showed the lowest CC frequency.

The frequency of the homozygous genotype TT2087 was higher in patients than in controls, but these differences were not statistically significant. The heterozygous genotype was more represented in controls than in patients, except for SMCS patients. The FM/CFS group showed the lowest CT genotype frequency (Table 1).

The analysis of the distribution of NOS3 gene variant −786T>C showed that allele and genotype frequencies were not significantly different between the groups. The T wild-type allele was more frequent than the C mutant one. The heterozygous genotype was the most represented in all groups.

3.2. Allele and Genotype Frequencies of the Pentanucleotide Microsatellite −2.5 kb (CCTTT)_n in NOS2A Promoter. Genotyping results showed that the NOS2A −2.5 kb (CCTTT)_n repeat variant was present with nine different alleles (ranging 8–16 repeats, 176–216 bp) both in patients and controls, with an unimodal distribution having a peak at the (CCTTT)_{12} allele that was the most frequent in all examined groups (Table 2). The (CCTTT)_7 and (CCTTT)_17 alleles were not found in our study cohort.

The estimation of linkage disequilibrium for NOS2A C2087T and −2.5 kb (CCTTT)_n alleles showed that NOS2A C2087T is not in linkage disequilibrium with the microsatellite s/l allelic classification (D' = 0.112, LOD = 0.24, r^2 = 0.003).
Table 2: Allelic distributions of the NOS2A promoter pentanucleotide microsatellite −2.5 kb (CCTTT)₈ in IEI patients and healthy subjects.

| Genotype NOS2A −2.5 kb (CCTTT)₈ | MCS (N = 170) | SMCS (N = 108) | FM/CFS (N = 89) | Controls (N = 196) |
|---------------------------------|--------------|---------------|---------------|------------------|
| 8                              | 0.03a        | 0.02b         | 0c            | 0.09             |
| 9                              | 0.07         | 0.09          | 0.04          | 0.08             |
| 10                             | 0.17         | 0.19          | 0.18          | 0.18             |
| 11                             | 0.15         | 0.16          | 0.26d         | 0.09             |
| 12                             | 0.28         | 0.27          | 0.32          | 0.27             |
| 13                             | 0.15         | 0.08          | 0.10          | 0.12             |
| 14                             | 0.07         | 0.05          | 0.04          | 0.06             |
| 15                             | 0.07         | 0.08          | 0.04          | 0.07             |
| 16                             | 0.01e,f      | 0.08          | 0.02          | 0.04             |

MCS, multiple chemical sensitivity; SMCS: suspected multiple chemical sensitivity; FM/CFS, fibromyalgia/chronic fatigue syndrome; controls, healthy subjects. a: P = 0.0094, significant difference in comparison with controls; b: 0.0482, significant difference versus controls; c: P = 0.026, significant difference versus controls; d: P = 0.0031, significant difference versus controls; e: P = 0.0426, significant difference versus controls; f: P = 0.0057, significant difference versus SMCS.

The (CCTTT)₈ allele was more frequent in controls than in patients, showing a prevalence three-fourfold higher in controls than in MCS and SMCS patients. This difference was highly significant in comparison with MCS patients (P < 0.01) and significant in comparison with SMCS patients (P < 0.05); this allele was not observed among FM/CFS patients (Table 2). Notably, the presence of the (CCTTT)₈ allele was associated with a decreased risk of IEI, since it reduced by threefold the risk for MCS (OR = 0.3; 95% C.I. = 0.12–0.77), by sixfold the risk for SMCS (OR = 0.16; 95% C.I. = 0.021–1.24), and by tenfold the risk for FM/CFS (OR = 0.09; 95% C.I. = 0.0057–1.65).

The (CCTTT)₈ allele and the (CCTTT)₁₂ allele had a lower and higher frequency, respectively, in FM/CFS patients than in all other groups that showed similar frequencies. The (CCTTT)₁₀ allele had similar frequencies in all groups (Table 2).

The (CCTTT)₁₃ allele frequency was around threefold higher in FM/CFS patients than in controls, and this difference was statistically significant (P < 0.01) (Table 2). Moreover, a difference tending to statistical significance was found when comparing FM/CFS patients with MCS (P = 0.06). This NOS2A variant was associated with a significantly increased risk for FM/CFS (OR = 3.557, 95% C.I. 1.575–8.033).

The (CCTTT)₁₄ allele was more represented in controls than in other groups and had a frequency almost double than in SMCS patients, but these differences were not statistically significant. The (CCTTT)₁₄ and (CCTTT)₁₅ alleles had similar frequencies in all groups.

The (CCTTT)₁₆ allele was more represented in SMCS patients than in other groups, with a frequency that was eight- and twofold higher than in MCS patients and controls, respectively, but this difference was statistically significant (P < 0.01) only in comparison with MCS patients, while tended to be significant when compared with controls (P < 0.06). The lowest frequency was observed in MCS patients, with a significant difference in comparison with controls (P < 0.05).

The (CCTTT)₈ genotype frequencies did not deviate from the expected value by Hardy-Weinberg equilibrium. The (CCTTT)₈/₁₃ genotype was only found in controls, with a frequency of 4.5%.

The (CCTTT)₁₂ allele was mostly represented in homozygous state in all examined groups. The (CCTTT)₁₂/₁₂ genotype was the most frequent in all examined group except in FM/CFS (16.9% MCS, 12.5% SMCS, 12% FM/CFS, and 16.9% controls). In this latter group, the most represented genotype was the (CCTTT)₁₀/₁₂ genotype that showed a significantly higher frequency when compared with MCS patients (20 versus 2.5%; P = 0.0044) and a borderline significant difference when compared with controls (20 versus 6.7%; P = 0.061), while frequencies in SMCS patients and controls were similar (6.3% versus 6.7%, P > 0.05).

The (CCTTT)₁₀/₁₀ genotype, having a frequency around 7% in MCS, SMCS, and controls, was not found in FM/CFS patients. The (CCTTT)₁₀/₁₁ in MCS patients had a frequency double than that in controls (10.2 versus 4.5%, not significant), while in SMCS patients and FM/CFS it accounted for 6.3% and 8.0%, respectively.

The (CCTTT)₁₁/₁₁ genotype had the highest frequency in FM/CFS patients (8% versus 3% in all other groups), but this difference did not reach statistically significant values.

The (CCTTT)₁₁/₁₂ genotype had the highest frequency in SMCS patients (12.5% versus 3.4% MCS versus 8% FM/CFS versus 3.4% controls), but this difference was not statistically significant.

The (CCTTT)₁₁/₁₃ genotype was more represented in FM/CFS patients than in other groups, with a frequency significantly different when compared with SMCS (16 versus 0%; P = 0.032) and controls (16 versus 1.1%; P = 0.008) and borderline significant when compared with MCS (16 versus 4.2%; P = 0.0501). Moreover, this genotype was associated with an increased risk for FM/CFS (OR = 16.8; 95% C.I. = 1.78–157.9).

The (CCTTT)₁₃/₁₃ genotype had the highest frequency in MCS patients (6.8% versus 3.1% SMCS versus 0% FM/CFS versus 4.5% controls), but this difference was not statistically significant.

All other allele combinations did not reach a frequency higher than 5% in all groups.
In an attempt to better understand whether the presence of increasing \(-2.5\; kb\) \((\text{CCTTT})\) repeat numbers of NOS2A promoter may be a genetic feature useful to discriminate different types of IEI, we grouped together different genotypes by classifying alleles with repeat number \(<12\) as short \((s)\) and alleles with repeat number \(\geq 12\) as long \((l)\). The between-groups comparison of \(s\) and \(l\) allele frequencies showed that there were no significant differences between different groups of patients and also between patients and controls.

The homozygous genotype \((\text{CCTTT})_{\text{short}}/(\text{CCTTT})_{\text{long}}\) \((sl)\) showed the highest frequencies in FM/CFS and SMCS patients that were significantly different in comparison with both controls \((P < 0.001, \; P = 0.02,\; \text{resp.})\) and MCS patients \((P < 0.001, \; P = 0.005,\; \text{resp.})\); additionally, SMCS patients having the \((\text{CCTTT})_{\text{sl}}\) genotype were found to be significantly different from FM/CFS \((P = 0.0016)\). Notably, this genotype increased by about fivefold and twofold, respectively, the risk for FM/CFS \((\text{OR} = 4.8; \; \text{C.I.} = 2.813–8.211)\) and SMCS \((\text{OR} = 1.9; \; \text{C.I.} = 1.129–3.048)\). Finally, the homozygous genotype \((\text{CCTTT})_{\text{ll}}\) may be useful for diagnosis of either SMCS or FM/CFS states and discrimination between SMCS and either MCS or FM/CFS.

The \((\text{CCTTT})_{\text{long}}/(\text{CCTTT})_{\text{long}}\) \((ll)\) genotype had the lowest frequency in FM/CFS patients and statistically significant differences were found in comparison with all other groups \((\text{MCS}: \; P < 0.0001; \; \text{SMCS}: \; P = 0.04;\; \text{controls}: \; P = 0.0002)\). Therefore, the \((\text{CCTTT})_{\text{ll}}\) genotype may be useful to discriminate FM/CFS patients from both MCS and SMCS patients.

The \((\text{CCTTT})_{\text{short}}/(\text{CCTTT})_{\text{short}}\) \((ss)\) genotype showed the lowest frequency in FM/CFS patients that were significantly different in comparison with controls \((P = 0.012)\) and MCS patients \((P = 0.015)\). Moreover, this genotype was protective against FM/CFS since it reduced by 2.5-fold the disease risk \((\text{OR} = 0.4334; \; \text{C.I.} = 0.2269–0.8280)\).

3.3. Influence of NOS2A and NOS3 Polymorphisms on the Variability of Nitrite/Nitrate Plasma Levels. Analysis of nitrite/nitrate plasma concentrations showed that IEI patients recruited for this study exhibited similar levels of these proinflammatory markers \((26.2 \pm 13.3\; \mu\text{mol/L}\; \text{MCS}; \; 24.7 \pm 12.2\; \text{SMCS}; \; 28.4 \pm 15.2\; \text{FM/CFS})\). Notably, nitrite/nitrate concentrations in patients were around or more than twofold higher than in controls \((27.1 \pm 13.8\; \text{versus} \; 15.3 \pm 5.2\; \mu\text{mol/L})\), and this difference was statistically significant \((P = 0.037)\).

We analyzed the variability of nitrite/nitrate concentrations in patients and controls having different NOS2A and NOS3 genotypes. Patients with different NOS2 \(C2087T\) genotypes showed different nitrite/nitrate levels, even if these differences did not reach statistical significance. In particular, TT homozygous mutated patients showed higher nitrite/nitrate concentrations than patients with other genotypes, while controls with different genotypes exhibited similar mean nitrite/nitrate plasma levels. TT homozygous patients had higher nitrite/nitrate levels compared with controls with the same genotype, while wild-type patients showed lower nitrite/nitrate levels than controls. However, no significant differences were observed when comparing patients and controls with different genotypes (Figure 1(a)). We tried to better investigate the between-groups differences, if present, by dividing IEI patients on the basis of their diagnosis. Again, no significant differences were found between different groups of patients and controls (Figure 1(b)).

When nitrite/nitrate levels were analyzed in patients and controls with different NOS3 \(-786\; T > C\) genotypes, some
statistically significant differences were found. In particular, nitrite/nitrate levels were significantly higher in TT wild-type patients than in either TC heterozygous or CC mutated patients ($P = 0.012$, $P = 0.0007$, resp.). Moreover, when comparing controls and patients a statistically significant difference was observed between TC heterozygous subjects, since controls showed higher nitrite/nitrate levels than patients with the same genotype (Figure 2(a)). When patients were divided in subgroups on the basis of different diagnosis, significant differences were found between either MCS or SMCS patients with TT genotype and controls having the same genotype ($P = 0.04$, $P = 0.03$, resp.). Moreover, SMCS and FM/CFS patients bearing the CC genotype had significantly lower nitrite/nitrate plasma levels than either controls having the same genotype ($P = 0.002$, $P = 0.03$, resp.) or TC genotype ($P = 0.0005$, $P = 0.014$, resp.) (Figure 2(b)). Finally, MCS patients having the TT genotype had nitrite/nitrate levels significantly higher than either SMCS or FM/CFS patients with TC ($P = 0.008$, $P = 0.04$, resp.) and CC genotype ($P = 0.0001$, $P = 0.004$, resp.) and MCS patients having either TC or CC genotype ($P = 0.004$, $P = 0.03$, resp.) (Figure 2(b)).

Unfortunately, we could not analyze in detail the influence of the NOS2A −2.5 kb (CCTTT)$_s$ pentanucleotide microsatellite on the variation of nitrite/nitrate plasma levels due to the dramatically high fragmentation of our study cohort caused by the high number of combinations of different NOS2A −2.5 kb (CCTTT) alleles. However, we tried to detect differences among patient subgroups by grouping (CCTTT) repeats as short (s) when <12 or long (l) when ≥12. By this way, we obtained three types of allele combinations, namely, (CCTTT)$_s$/(CCTTT)$_s$, (CCTTT)$_s$/(CCTTT)$_l$, and (CCTTT)$_l$/(CCTTT)$_l$. Then, we compared patients, grouped together (Figure 3(a)) or separated according to their diagnosis (Figure 3(b)), with controls having the same allele combinations. The results showed that nitrite/nitrate plasma levels were significantly higher in all patients and controls having the (CCTTT)$_s$/(CCTTT)$_s$ allele combination compared with patients and controls having the (CCTTT)$_l$/(CCTTT)$_l$ allele combination ($P = 0.0002$, $P = 0.004$, resp.) (Figure 3(a)). Moreover, while examining the subgroups of patients significant differences were found between MCS patients having the (CCTTT)$_s$/(CCTTT)$_l$ allele combination and those with (CCTTT)$_l$/(CCTTT)$_l$ allele combination ($P = 0.008$) (Figure 3(b)). However, two-way ANOVA, making a between-groups comparison, showed that nitrite/nitrate plasma levels were neither significantly different in subgroups of patients having different (CCTTT)$_l$ and (CCTTT)$_l$ allele combinations nor significantly different in comparison with controls having the same allele combinations (Figure 3(b)).

4. Discussion

Environment-associated pathologies have been attracting growing attention in the recent years due to increasing daily exposure to various hazardous stimuli, such as chemicals, drugs, metals, electromagnetic or nuclear radiations, iatrogenic factors (including synthetic implants), specific foods, and microbial and environmental allergens [11]. Ethical, medical, and social/occupational impact of IEI is worsened by steadily growing population of hypersensitive people, not yet regulated diagnostic protocols, and abuse of not evidence-based treatments.
The most important studies on hypersensitive populations, especially MCS patients, have been concentrated on the search for genetic determinants of abnormal sensitivity. Based on the primary hypothesis of an impairment in the metabolism of xenobiotics, a wide variety of polymorphisms of genes encoding for phases I and II of detoxification enzymes were studied, such as CYPs, GST, COMT, UGT, NAT, and PON, with conflicting results [6, 10, 24–26]. Our group recently demonstrated that gene variants of GST and CYP isoforms, namely, GSTP1, GSTM1, GSTT1, CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2D6*4, and CYP2D6*41, proven to be useful for diagnostic assessment of IEI patients [6, 7, 10, 11].

A number of years ago, Pall and Satterlee [14] postulated the existence of a vicious nitric oxide/peroxynitrite cycle as the basis for IEI, starting from several observations: (1) several organic solvents, which induce chemical sensitization (formaldehyde, benzene, carbon tetrachloride, and certain organochlorine pesticides), trigger increases in nitric oxide levels; (2) organophosphate and carbamate insecticides are suggested to induce MCS by inactivating acetylcholinesterase and thus activating muscarinic response, which is known to produce increases in nitric oxide; (3) elevated cytokines, an integral part of the proposed feedback mechanism of the elevated nitric oxide/peroxynitrite theory, are known to be induced by organic solvents through NOS2 activation; (4) antioxidant therapy has been reported to improve IEI symptoms, as expected if the levels of oxidant peroxynitrite are elevated; (5) the symptoms exacerbated after chemical exposure may be explained by several known proinflammatory properties of nitric oxide, peroxynitrite, and inflammatory cytokines, each of which have a role in the proposed mechanism; and (6) IEI are often treated through intramuscular injections of vitamin B12, that, in the form of hydroxocobalamin, is a potent nitric oxide scavenger in vitro and in vivo.

Lately, it has been reported that nitrite/nitrate levels, responsible for lipid peroxidation and cytokine increase, are significantly increased in IEI patients [11]. Interestingly, circulating NO and consequently nitrate/nitrite levels may be altered by the presence of NOS polymorphisms [21, 27, 28]. Moreover, some NOS variants, particularly the NOS2

---

**Figure 3:** Effects of different NOS2 −2.5 kb (CCTTT)$_s$ short (s) versus long (l) repeats alleles on nitrite/nitrate plasma levels in IEI patients (MCS = 170; SMCS = 108; FM/CFS = 89), grouped together (a) or separated (b), and controls ($N = 196$). Box-plots graphically depict the variation in plasma nitrite/nitrate concentrations of patients and healthy subjects, having different NOS2 −2.5 kb (CCTTT)$_s$ genotypes, through their quartiles. The bottom and top of the boxes are the first and third quartiles, and the band inside the boxes is the second quartile (the median); lines extending vertically from the boxes (whiskers) indicate variability outside the upper and lower quartiles (the ends of the whiskers represent the minimum and maximum of all of the data). (a) ***$P < 0.01$, **$P < 0.001$ significant difference versus subjects with (CCTTT)$_s$/(CCTTT)$_s$ genotype; (b) $**P < 0.01$, significant difference versus MCS with (CCTTT)$_s$/(CCTTT)$_s$ genotype.
Ser608Leu as well as the pentanucleotide microsatellite −2.5 kb (CCTTT)$_n$ and the NOS3 −786T>C, were associated with either increased nitrite/nitrate levels, total serum immunoglobulin E, and blood eosinophil levels or cytokines in various allergic/inflammatory/autoimmune disorders, including atopy, asthma, migraine, inflammatory bowel disease, or rheumatoid arthritis [16–20, 29–33].

Given that allergic/inflammatory symptoms are common in IEI patients and that our patients were all exhibiting remarkably elevated nitrite/nitrate plasma levels compared to controls (27.1 ± 13.8 versus 15.3 ± 5.2 μM, $P < 0.05$), we chose to investigate the distribution of the polymorphic variants NOS2 −2.5 kb (CCTTT)$_n$ and Ser608Leu and NOS3 −786T>C in IEI patients.

We did not find significant difference in the distribution of the polymorphic variants NOS2A C2087T (Ser608Leu) and NOS3 −786T>C when patient groups were compared with controls (Table 1). Allele and genotype frequencies in healthy subjects were similar to those reported in other European populations [29]. Moreover, while investigating the effects of these NOS2A and NOS3 variants on the variability of nitrite/nitrate plasma levels, we could not observe any effect of NOS2A C2087T. Unfortunately, no information is available on the influence of NOS C2087T on variation of these inflammatory markers. So, this is the first report documenting no apparent effect of the NOS2A Ser608Leu on the variation of nitrite/nitrate plasma levels.

Interestingly, we found that patients with the NOS3 −786TT wild-type genotype had significantly increased nitrite/nitrate levels in comparison with patients having other genotypes. This latter observation agrees with those previously reported in patients with coronary spastic angina and healthy subjects after exercise [21, 28] and is in contrast with others in patients with asthma [27]. We also tried to detect differences in nitrite/nitrate plasma levels between subgroups of patients having different genotypes. What we found is that the significant difference initially observed between plasma levels of nitrite/nitrate in TT patients and those of either TC or CC patients (Figure 2(a)) was largely attributable to MCS patients bearing the TT genotype that had nitrite/nitrate concentrations significantly higher than MCS, SMCS, and FM/CFS patients bearing either TC of CC genotype.

Notably, we detected a relationship between the −2.5 kb (CCTTT)$_n$ microsatellite in the promoter region of NOS2A and IEI (Table 2). The NOS2A −2.5 kb (CCTTT)$_n$ microsatellite has been so far associated with asthma, atopy, rheumatoid arthritis, and inflammatory bowel disease [17, 18, 29–31]. It represents an attractive disease-causing candidate for IEI, being a highly polymorphic marker (11 different alleles, ranging 7–17 repeats, and 171–221 bp) with a suggested effect in NOS2 transcription. Indeed, it has been reported that variations in the number of (CCTTT)$_n$ repeats are functionally important in the regulation of NOS2 transcription, leading to increase in NO production [34].

Highly significant differences have been reported in the (CCTTT)$_n$ allele frequencies between ethnically diverse populations [35]. The observed frequencies of this marker in our cohort of healthy subjects fell within the Caucasian pattern, with the peak at the 12-repeat allele [29, 31, 35, 36]. When we compared the distribution of the (CCTTT)$_n$ repeat within the control subjects with that of IEI patients, the 8-repeat allele showed a significantly decreased frequency in the groups of patients compared with controls (Table 2). The odds ratio calculation showed that the presence of this allele reduced the risk for the different types of IEI examined in this study, suggesting that this NOS2A variant may display a protective effect against these disorders.

On the contrary, the 11-repeat allele, showing a significantly increased frequency in the group of FM/CFS patients compared with controls, may be considered a genetic determinant for FM/CFS. Moreover, the (CCTTT)$_{16}$ allele, having a significantly different frequency between MCS and SMCS, may be used to discriminate these two types of IEI.

Moreover, taking into account different repeat cut offs (9, 11, 13, and 16 repeats), we found that a different number of NOS2A (CCTTT)$_n$ repeats could be used to discriminate between the different pathological conditions. Interestingly, when we grouped the (CCTTT)$_n$ alleles in two categories according to the number of repeats, that is, the alleles with <12 repeats were designated as s (short) and alleles with ≥12 repeats as l (long), as previously described [29], we found that the (CCTTT)$_s$/(CCTTT)$_l$ allele combination had the highest frequencies in FM/CFS and SMCS (Table 3). Therefore, this NOS2A allele combination may be useful for diagnosis of these two types of IEI. Moreover, the observed distribution of (CCTTT)$_s$/(CCTTT)$_l$ and (CCTTT)$_l$/(CCTTT)$_l$ allele combination (Table 3) confirms that SMCS patients had overlapping features with FM/CFS.

| Genotype         | MCS (n = 170) | SMCS (n = 108) | FM/CFS (n = 89) | Controls (n = 196) |
|------------------|---------------|---------------|-----------------|--------------------|
| (CCTTT)$_s$      | 29.4%§§      | 25.0%         | 15.7%§§         | 30.1%              |
| (CCTTT)$_l$      | 70.6%        | 75.0%         | 84.3%           | 70.9%              |
| Allele frequency |               |               |                 |                    |
| (CCTTT)$_s$      | 0.4           | 0.5           | 0.5             | 0.4                |
| (CCTTT)$_l$      | 0.6           | 0.5           | 0.5             | 0.6                |

MCS, multiple chemical sensitivity; SMCS, suspected multiple chemical sensitivity; FM/CFS, fibromyalgia/chronic fatigue syndrome; controls, healthy subjects.

## Table 3: Genotype and allele frequencies of the NOS2A promoter pentanucleotide microsatellite −2.5 kb (CCTTT)$_n$ short and long repeats in IEI patients and healthy subjects.
and MCS and may be considered as an intermediate pathological condition between the two above cited.

After grouping of different (CCTTT) allele combinations, we were able to investigate the relationship between this polymorphic variant and nitrite/nitrate plasma levels in patients. Thus, we found that a short number of (CCTTT) repeats allele was associated with higher concentrations of nitrites/nitrates.

5. Conclusions

Our results demonstrated for the first time that the NOS2A promoter pentanucleotide microsatellite \(-2.5\) kb (CCTTT)\(_n\) is associated with FM/CFS and may be feasible for the diagnostic assessment of this type of IEI. Moreover, the screening for the presence of some NOS2A \(-2.5\) kb (CCTTT) variants, that is, the 8- and 16-repeat alleles, may be useful, respectively, to exclude the diagnosis of IEI and discriminate between MCS and SMCS.

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

This work was exclusively funded by departmental internal grants of collaborating institutions.

References

[1] C. de Luca, G. Scordo, E. Cesareo, D. Raskovic, G. Genovesi, and L. Korkina, "Idiopathic environmental intolerances (IEI): from molecular epidemiology to molecular medicine," Indian Journal of Experimental Biology, vol. 48, no. 7, pp. 625–635, 2010.

[2] L. Korkina, M. G. Scordo, I. Deeva, E. Cesareo, and C. de Luca, "The chemical defensive system in the pathobiology of idiopathic environment-associated diseases," Current Drug Metabolism, vol. 10, no. 8, pp. 914–931, 2009.

[3] H. M. Kipen and N. Fiedler, "Environmental factors in medically unexplained symptoms and related syndromes: the evidence and the challenge," Environmental Health Perspectives, vol. 110, supplement 4, pp. 597–599, 2002.

[4] L. H. Hetherington and J. M. Batterishill, "Review of evidence for a toxicological mechanism of idiopathic environmental intolerance," Human & Experimental Toxicology, vol. 32, no. 1, pp. 3–17, 2013.

[5] S. J. Genuis, "Chemical sensitivity: pathophysiology or pathopsychology?" Clinical Therapeutics, vol. 35, no. 5, pp. 572–577, 2013.

[6] G. McKeown-Eysse, C. Baines, D. E. C. Cole et al., "Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR," International Journal of Epidemiology, vol. 33, no. 5, pp. 971–978, 2004.

[7] D. Caccamo, E. Cesareo, S. Mariani et al., "Xenobiotic sensor- and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population," Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 831969, 9 pages, 2013.

[8] X. Cui, X. Lu, M. Hiura, M. Oda, W. Miyazaki, and T. Katoh, "Evaluation of genetic polymorphisms in patients with multiple chemical sensitivity," PLoS ONE, vol. 8, no. 8, Article ID e73708, 2013.

[9] C. de Luca, J. C. S. Thai, D. Raskovic et al., "Metabolic and genetic screening of electromagnetic hypersensitive subjects as a feasible tool for diagnostics and intervention," Mediators of Inflammation, vol. 2014, Article ID 924184, 14 pages, 2014.

[10] C. De Luca, M. G. Scordo, E. Cesareo et al., "Biological definition of multiple chemical sensitivity from redox state and cytokine profiling and not from polymorphisms of xenobiotic-metabolizing enzymes," Toxicology and Applied Pharmacology, vol. 248, no. 3, pp. 285–292, 2010.

[11] C. de Luca, D. Raskovic, V. Pacífico, J. C. S. Thai, and L. Korkina, "The search for reliable biomarkers of disease in multiple chemical sensitivity and other environmental intolerances," International Journal of Environmental Research and Public Health, vol. 8, no. 7, pp. 2770–2797, 2011.

[12] M. L. Pall, "NMDA sensitization and stimulation by peroxynitrite, nitric oxide, and organic solvents as the mechanism of chemical sensitivity in multiple chemical sensitivity," The FASEB Journal, vol. 16, no. 11, pp. 1407–1417, 2002.

[13] Y. Vodovozov, P. K. M. Kim, E. Z. Bagci et al., "Inflammatory modulation of hepatocyte apoptosis by nitric oxide: in vivo, invitro, and in silico studies," Current Molecular Medicine, vol. 4, no. 7, pp. 753–762, 2004.

[14] M. L. Pall and J. D. Satterlee, "Elevated nitric oxide/peroxynitrite mechanism for the common etiology of multiple chemical sensitivity, chronic fatigue syndrome, and posttraumatic stress disorder," Annals of the New York Academy of Sciences, vol. 933, pp. 323–329, 2001.

[15] M. L. Pall, "Elevated nitric oxide/peroxynitrite theory of multiple chemical sensitivity: central role of N-methyl-d-aspartate receptors in the sensitivity mechanism," Environmental Health Perspectives, vol. II, no. 12, pp. 1461–1464, 2003.

[16] L. I. Holla, A. Stejskalova, V. Znojil, and A. Vasku, "Analysis of the inducible nitric oxide synthase gene polymorphisms in Czech patients with atopic diseases," Clinical & Experimental Allergy, vol. 36, no. 12, pp. 1592–1601, 2006.

[17] S. Konno, N. Hizawa, E. Yamaguchi, E. Jinushi, and M. Nishimura, "(CCTTT)\(_n\) repeat polymorphism in the NOS2 gene promoter is associated with atopy," Annals of Allergy and Clinical Immunology, vol. 108, no. 5, pp. 810–814, 2001.

[18] J. Batra, T. P. Singh, U. Mabalirajan, A. Sinha, R. Prasad, and B. Ghosh, "Association of inducible nitric oxide synthase with asthma severity, total serum immunoglobulin E and blood eosinophil levels," Thorax, vol. 62, no. 1, pp. 16–22, 2007.

[19] F. M. Gonçalves, M. R. Luizon, J. G. Speciali, A. Martins-Oliveira, F. Dach, and J. E. Tanus-Santos, "Interaction among nitric oxide (NO)-related genes in migraine susceptibility," Molecular and Cellular Biochemistry, vol. 370, no. 1-2, pp. 183–189, 2012.

[20] S. S. Dhillon, L. A. Mastropaolo, R. Murchie et al., "Higher activity of the inducible nitric oxide synthase contributes to very early onset inflammatory bowel disease," Clinical and Translational Gastroenterology, vol. 5, no. 1, article e46, 2014.

[21] Y. Miyamoto, Y. Saito, M. Nakayama et al., "Replication protein AI reduces transcription of the endothelial nitric oxide synthase gene containing a \(-786T \rightarrow C\) mutation associated with coronary spastic angina," Human Molecular Genetics, vol. 9, no. 18, pp. 2629–2637, 2000.
[22] C. S. Miller and T. J. Prihoda, “The environmental exposure and sensitivity inventory (EESI): a standardized approach for measuring chemical intolerances for research and clinical applications,” Toxicology and Industrial Health, vol. 15, no. 3-4, pp. 370–385, 1999.

[23] G. E. Brown, G. M. Silver, J. Reiff, R. C. Allen, and M. P. Fink, “Polymorphonuclear neutrophil chemiluminescence in whole blood from blunt trauma patients with multiple injuries,” Journal of Trauma, vol. 46, no. 2, pp. 297–305, 1999.

[24] E. Schnakenberg, K.-R. Fabig, M. Stanulla et al., “A cross-sectional study of self-reported chemical-related sensitivity is associated with gene variants of drug-metabolizing enzymes,” Environmental Health, vol. 6, article 6, 2007.

[25] G. A. Wiesmüller, H. Niggemann, W. Weißbach et al., “Sequence variations in subjects with self-reported multiple chemical sensitivity (sMCS): a case-control study,” Journal of Toxicology and Environmental Health Part A: Current Issues, vol. 71, no. 11-12, pp. 786–794, 2008.

[26] N. D. Berg, H. Berg Rasmussen, A. Linneberg et al., “Genetic susceptibility factors for multiple chemical sensitivity revisited,” International Journal of Hygiene and Environmental Health, vol. 213, no. 2, pp. 131–139, 2010.

[27] E. Bouzigon, F. Monier, M. Boussaha et al., “Associations between nitric oxide synthase genes and exhaled NO-related phenotypes according to asthma status,” PLoS ONE, vol. 7, no. 5, Article ID e36672, 2012.

[28] C. H. Sponton, R. Esposti, C. M. Rodovalho et al., “The presence of the NOS3 gene polymorphism for intron 4 mitigates the beneficial effects of exercise training on ambulatory blood pressure monitoring in adults,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 306, no. 12, pp. H1679–H1691, 2014.

[29] M. A. Gonzalez-Gay, J. Llorca, E. Sanchez et al., “Inducible but not endothelial nitric oxide synthase polymorphism is associated with susceptibility to rheumatoid arthritis in northwest Spain,” Rheumatology, vol. 43, no. 9, pp. 1182–1185, 2004.

[30] M. C. Martin, A. Martinez, J. L. Mendoza et al., “Influence of the inducible nitric oxide synthase gene (NOS2A) on inflammatory bowel disease susceptibility,” Immunogenetics, vol. 59, no. 11, pp. 833–837, 2007.

[31] M. Pascual, M. A. López-Nevot, R. Cáliz et al., “Genetic determinants of rheumatoid arthritis: The inducible nitric oxide synthase (NOS2) gene promoter polymorphism,” Genes & Immunity, vol. 3, no. 5, pp. 299–301, 2002.

[32] T. D. O. S. Mansur, F. M. Gonçalves, A. Martins-Oliveira et al., “Inducible nitric oxide synthase haplotype associated with migraine and aura,” Molecular and Cellular Biochemistry, vol. 364, no. 1-2, pp. 303–308, 2012.

[33] R. Eröz, A. Bahadir, S. Dikici, and S. Tasdemir, “Association of endothelial nitric oxide synthase gene polymorphisms (894G/T, -786T/C, G10T) and clinical findings in patients with migraine,” NeuroMolecular Medicine, vol. 16, no. 3, pp. 587–593, 2014.

[34] K. M. Warpeha, W. Xu, L. Liu et al., “Genotyping and functional analysis of a polymorphic (CCTTT)n repeat of NOS2A in diabetic retinopathy,” The FASEB Journal, vol. 13, no. 13, pp. 1825–1832, 1999.

[35] W. Xu, S. Humphries, M. Tomita et al., “Survey of the allelic frequency of a NOS2A promoter microsatellite in human populations: Assessment of the NOS2A gene and predisposition to infectious disease,” Nitric Oxide—Biology and Chemistry, vol. 4, no. 4, pp. 379–383, 2000.

[36] M. Pascual, C. Sanz, M. Isidoro-García et al., “(CCTTT)n polymorphism of NOS2A in nasal polyposis and asthma: a case-control study,” Journal of Investigational Allergology and Clinical Immunology, vol. 18, no. 4, pp. 239–244, 2008.